Navigation Links
Suits Commenced Against Maker of Prescription Cleansing Drug
Date:12/23/2009

GREENSBORO, N.C., Dec. 23 /PRNewswire/ -- Suits were commenced Dec. 23, 2009 in North Carolina for four users who allege kidney damage due to the use of OsmoPrep, a prescription drug used to cleanse the intestines in preparation for a colonoscopy. (Holshouser et al v. Salix Pharmaceuticals, Ltd. and Salix Pharmaceuticals. Inc.)

The actions are against two Morrisville, N.C., pharmaceutical companies, Salix Pharmaceuticals, Ltd., and Salix Pharmaceuticals, Inc. ( SLXP). The company, which specializes in marketing gastrointestinal drugs, began selling OsmoPrep in 2006. It had over $30 million in sales in 2008.

OsmoPrep contains two types of sodium phosphates, which work by drawing water in the bowels. A large number of pills are taken the day before and the day of the colonoscopy. Salix also sells a product, Visicol, with similar chemicals and has the same purpose.

In December 2008, after receiving a number of reports of kidney injury, the FDA required Salix to place a black box warning on the product, as to serious kidney damage occurring after use of OsmoPrep and also Visicol. A black box warning is the most strict type of warning that the FDA can force a drug supplier to use in its labeling.

Also as a condition for continuing to market OsmoPrep, the FDA required Salix to perform what is known as a REMS evaluation--Risk Evaluation and Mitigation Strategies. These are designed to determine which population is more at risk in using the product, such as older person, those who are dehydrated or have pre-existing kidney damage, and those concurrently on other drugs.

The liquid form of these oral phosphates had been used in Fleet Phospho-Soda, an over-the-counter product manufactured by C. B. Fleet in Virginia. Fleet withdrew this product from the market in December 2008 in response to a similar request from the FDA to enhance its warnings.

The four plaintiffs in this suit, which was filed in Burke County, N.C., sustained a variety of serious kidney injuries, including the need for dialysis. The medical name for the condition they have suffered is acute phosphate nephropathy.

The complaint alleged that Salix was aware of the risks of serious kidney damage at the time of first marketing OsmoPrep and up until the FDA forced the black box warning. Such information came from articles in the medical literature and individual case reports.

The suit was commenced by the Greensboro, N.C., firm of WardBlackLaw, with assistance of the firm of Rheingold, Valet, Rheingold, Shkolnik and McCartney LLP, of New York City. The Rheingold firm is also involved with the Fleet Phospho-Soda litigation which has been consolidated in Cleveland, OH.


    Contact: Paul D. Rheingold
    Rheingold, Valet, Rheingold, Shkolnik & McCartney LLP
    113 East 37th Street
    New York, NY 10016
    (212) 684-1880
    prheingold@rheingoldlaw.com

SOURCE Rheingold, Valet, Rheingold, Shkolnik & McCartney LLP


'/>"/>
SOURCE Rheingold, Valet, Rheingold, Shkolnik & McCartney LLP
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent
2. Arnold & Itkin Announces Lawsuits Over Defective Pain Pumps
3. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
4. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
5. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
6. Molnlycke Drives Home the Fight Against Staph and Other MRSA Infections
7. Mayo Clinic Study Finds FDA Warning Against Anti-Nausea Drug Droperidol Unnecessary
8. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
11. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Israel , December 5, 2016 ... identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase ... BL-8040, the Company,s leading oncology platform at the ongoing 58th ... San Diego, California . ... , , ...
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 ... showed non-inferiority to hydroxyurea (HU) in Complete Hematologic Response (CHR) ... tolerability profile of ropeginterferon alfa-2b versus HU ... long-term follow-up trial CONTINUATION-PV to obtain European marketing authorization in ... this data to the FDA as it seeks approval for ...
(Date:12/4/2016)... HOUSTON , Dec. 3, 2016   Pairnomix, LLC, ... Precision Medicine Alliance (PEPMA) recognized by the White House, today ... individualized approach to the identification of candidate therapies for a ... SCN8A gene were presented at the 70 th ... in Houston, TX , December 2-6, 2016.  ...
Breaking Medicine Technology:
(Date:12/5/2016)... , ... December 05, 2016 , ... ... it has been featured in SuperbCrew magazine, a leading online tech news platform ... This interview, now featured on SuperbCrew.com, explores the state of enterprise mobility security ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... today that nominations will be accepted from December 5, 2016 through March ... Awards include the Information Security Executive® of the Year, which recognizes executives ...
(Date:12/5/2016)... ... December 05, 2016 , ... Researchers at Johns Hopkins All ... brains of young athletes. Over the course of three years, researchers will study concussions ... guards. The mouth guards, equipped with special sensors, will track the location and force ...
(Date:12/5/2016)... ... December 05, 2016 , ... Worldwise ®, a leading ... firm kathy ireland® Worldwide for five additional years, announced by Kevin Fick, Worldwise ... licensing agreement three years ago to design and develop the kathy ireland® Loved ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy Awareness,” which can be ... sparks a conversation about epilepsy, bearing down on the social stigma and lack ... diagnosed with epilepsy within their lifetime. With such a large percentage of people ...
Breaking Medicine News(10 mins):